Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New canine oral cancer drug to be trialled
Owners of dogs with oral melanoma are being encouraged to participate in the trial.
The drug is already licensed to another form of canine cancer.

A pilot trial is set to be carried out to test the ability of a drug derived from berries to treat canine oral melanoma.

Researchers at the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland will assess the effectiveness of the drug tigilanol tiglate, which is derived from the berries of the blushwood tree, a species found in Queensland, Australia.

The drug, which disrupts blood vessels inside tumours without harming healthy tissue, is currently licensed to treat mast cell tumours. If it is shown to work to treat canine oral melanoma, it may save some dogs from having to undergo surgery.

The researchers hope that the trial could also provide insights that could benefit human medicine, as canine oral melanoma shares many features with human mucosal melanoma. In both diseases, symptoms typically remain hidden until the disease has already reached an advanced stage.

The research is being funded by QBiotics, the manufacturer of tigilanol tiglate, which it sells under the brand name Stelfonta.

The trial will involve eight dogs, although the number of participating animals may be increased if the initial results prove to be promising. Owners of eligible dogs are being asked to get in touch with the research team.

Kelly Blacklock, professor of small animal soft tissue surgery, said: “If successful, this treatment could transform the way we approach cancer therapy in veterinary medicine, sparing many dogs from the need for surgery.

“We encourage pet owners with dogs diagnosed with oral melanoma to consider participating in this trial. Your involvement could not only contribute to advancing treatment options for this challenging disease but also help improve the quality of life for dogs in the future.”

Eligible dog owners wishing to take part should email Professor Blacklock.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Bluetongue reaches Wales for first time in 2025

The Animal and Plant Health Agency (APHA) has revealed that bluetongue has been confirmed in Wales for the first time in 2025.

In their latest statistics, APHA records a total of 109 cases of BTV-3 or BTV-8 in Great Britain in the 2025-2026 vector season.

The total number of BTV-3 cases in Great Britain this season is 107. This includes 103 cases within the England restricted zone and four cases in Wales.

There has also been two cases of BTV-8, which were both in Cornwall.

As a result of the cases in Wales, a Temporary Control Zone (TCZ) is enforced in Monmouthshire. Animals can move freely under general license within the England Restricted Zone, however animals with suspected bluetongue must stay on their holding.

All premises testing positive for blue tongue can be viewed on this map.